<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00867594</url>
  </required_header>
  <id_info>
    <org_study_id>0566-08-HMO-CTIL</org_study_id>
    <nct_id>NCT00867594</nct_id>
  </id_info>
  <brief_title>Effectiveness of Oral Insulin in Unstable Type 1 Diabetes Patients</brief_title>
  <official_title>A Single Blind, Open-Label Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral Insulin Formulation in Type 1 Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oramed Pharmaceutical Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <brief_summary>
    <textblock>
      The intent of the proposed study is to assess the potential of oral insulin to mitigate
      diabetic instability and reduce the frequency and severity of hypoglycemic episodes in
      patients with type 1 diabetes. Restoring hepatic glycogen stores is critical for the
      normalization of counter-regulation to hypoglycemia in these patients. Oral insulin can
      provide a means to increase portal insulin levels, shift the ratio of insulin/glucagon in
      favor of glycogenesis while sparing the patient the risk of hypoglycemia due to peripheral
      hyperinsulinemia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety and tolerability of multi-doses of Oramed oral insulin in people with type 1 diabetes</measure>
    <time_frame>15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine if oral insulin is likely to improve glycemic stability assessed by the reduction of the frequency and severity of hypoglycemic episodes in people with unstable type 1 diabetes</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Brittle Type I Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORMD 0801</intervention_name>
    <description>1 capsule ORMD 0801 3 times a day, before each meal</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Male or female aged 18-50 years inclusive

          -  Body weight between 50-100kg and BMI between 18 and 30 kg/m2

          -  Diagnosed 6 or more months ago, unstable diabetes with frequent episodes of
             hypoglycemia

          -  No other medical problems

        Exclusion Criteria:

          -  History or presence of clinical significant gastrointestinal pathology or symptoms,
             liver or kidney disease or any condition that might interfere with the absorption,
             distribution, metabolism or excretion of the drug

          -  Positive pregnancy test or lactation

          -  Lack of family support

          -  Unwilling or unable to follow the study protocol

          -  Concurrent medical problems
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy Eldor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2009</study_first_submitted>
  <study_first_submitted_qc>March 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2009</study_first_posted>
  <last_update_submitted>August 10, 2011</last_update_submitted>
  <last_update_submitted_qc>August 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Roy Eldor</name_title>
    <organization>Hadassah Medical Organization, Jerusalem</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

